Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort

Fig. 1

Flow chart of eligible patients and treatment courses after each inclusion step. 1Patients with sicca symptoms but without Sjögren’s disease diagnosis were excluded (n = 2417). b/tsDMARD, biologic/ targeted synthetic disease-modifying anti-rheumatic drug; FU, follow-up; JAKi, Janus kinase-inhibitor; OMA, other modes of action; SCQM, Swiss Clinical Quality Management in Rheumatic Diseases; SjD, Sjögren’s disease; TC, treatment course; TNFi, Tumour necrosis factor-inhibitor

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us